Ricardo Ocaña-Riola

Dr. Ricardo Ocaña-Riola

Escuela Andaluza de Salud Pública
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2014 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
PDF file
EBEncarnación Blanco-Reina
Encarnación Blanco-Reina
GAGabriel Ariza‐Zafra
Gabriel Ariza‐Zafra
RORicardo Ocaña-Riola
Ricardo Ocaña-Riola
MLMatilde León‐Ortiz
Matilde León‐Ortiz

1 December 2014 in Environmental Pollution
Verified
Journal Article
Closed access
Juan Pedro ArrebolaJuan Pedro Arrebola
Juan Pedro Arrebola
RORicardo Ocaña-Riola
Ricardo Ocaña-Riola
AAAntonio L. Arrebola-Moreno
Antonio L. Arrebola-Moreno
MFMaría Fernández-Rodríguez
María Fernández-Rodríguez
PMPiedad Martin-Olmedo
Piedad Martin-Olmedo
NONicolás Olea
Nicolás Olea

11 November 2004 in Journal of Periodontal Research
Verified
Journal Article
Closed access
PDF file
ACA. Cueto
A. Cueto
Francisco MesaFrancisco Mesa
Francisco Mesa
MBManuel Bravo
Manuel Bravo
RORicardo Ocaña-Riola
Ricardo Ocaña-Riola

9 November 2014 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
EBEncarnación Blanco-Reina
Encarnación Blanco-Reina
GAGabriel Ariza-Zafra
Gabriel Ariza-Zafra
RORicardo Ocaña-Riola
Ricardo Ocaña-Riola
MLMatilde León-Ortíz
Matilde León-Ortíz
IBInmaculada Bellido-Estévez
Inmaculada Bellido-Estévez

16 May 2007 in Social Indicators Research
Verified
Journal Article
Closed access
PDF file
Carmen Sánchez-Cantalejo GarridoCarmen Sánchez-Cantalejo Garrido
Carmen Sánchez-Cantalejo Garrido
RORicardo Ocaña-Riola
Ricardo Ocaña-Riola
AFAlberto Fernández-Ajuria
Alberto Fernández-Ajuria

1 December 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EBEncarnación Blanco-Reina
Encarnación Blanco-Reina
MGMaria Rosa García-Merino
Maria Rosa García-Merino
RORicardo Ocaña-Riola
Ricardo Ocaña-Riola
LALorena Aguilar-Cano
Lorena Aguilar-Cano
JVJennifer Valdellós
Jennifer Valdellós
GAGabriel Ariza-Zafra
Gabriel Ariza-Zafra
Emerging and changing evidence made it necessary to update STOPP-START criteria, and version 2 was published recently. In this study the objectives were to determine the prevalence of potentially inappropriate medication prescribing (PIM) in primary care using STOPP versions 1 (v1) and 2 (v2), as well as 2012 AGS Beers criteria, and analyze the factors associated with inappropriate prescribing according to STOPP/START v2. A cross-sectional study was carried out including community-dwelling older adults over the age of 65. Sociodemographic, clinical, functional and comprehensive drug therapy data were collected. The primary endpoint was the percentage of patients receiving at least one PIM. This variable was measured using three tools: STOPP v1, 2012 AGS Beers criteria and STOPP v2. Similarly, the percentage of patients receiving at least one potential prescribing omission (PPO) was calculated using START versions 1 and 2. A total of 1,615 prescriptions were reviewed. The median number of medications per patient was 7.1 drugs (±3.8). The prevalence of elderly people exposed to polypharmacy (≥5 medications) was 72.9%, whereas 28.4% of the participants took ≥10 drugs regularly. PIM were present in 18.7%, 37.3% and 40.4% of participants, according to the STOPP v1, 2012 Beers criteria and STOPP v2, respectively. According to STOPP v2, the number of medications taken (OR: 1.14, 1.06–1.25), the presence of a psychological disorder (OR: 2.22, 1.13–4.37) and insomnia (OR: 3.35, 1.80–6.32) were risk factors for taking a PIM. The prevalence of PPOs was 34.7% and 21.8% according to version 1 and 2, respectively. In conclusion, STOPP-START criteria have been remarkably modified, which is evidenced by the different prevalence rates detected using version 2, as compared to version 1. In fact, the level of agreement between version 1 and the updated version is only moderate. Special attention should be paid on benzodiazepines, which keep being the most frequent PIM.